These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14072767)

  • 21. EFFECTS OF HOST HORMONES ON THE INTERNAL PARASITE, FASCIOLA HEPATICA.
    PANTELOURIS EM
    Res Vet Sci; 1965 Jul; 6():330-3. PubMed ID: 14342656
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of anthelmintic trial protocols using sheep experimentally or naturally infected with Fasciola hepatica.
    Smith G
    Vet Parasitol; 1984 Oct; 16(1-2):83-94. PubMed ID: 6543055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia.
    Elliott TP; Kelley JM; Rawlin G; Spithill TW
    Vet Parasitol; 2015 Apr; 209(1-2):117-24. PubMed ID: 25771931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UTILIZATION OF METHIONINE BY THE LIVER FLUKE, FASCIOLA HEPATICA.
    PANTELOURIS EM
    Res Vet Sci; 1965 Jul; 6():334-6. PubMed ID: 14342657
    [No Abstract]   [Full Text] [Related]  

  • 25. Experimental infection of liver flukes, Fasciola hepatica and Fascioloides magna, in Bison (Bison bison).
    Foreyt WJ; Drew ML
    J Wildl Dis; 2010 Jan; 46(1):283-6. PubMed ID: 20090045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anthelmintic efficiency of tetrachlorodifluoroethane against Fasciola hepatica in sheep.
    BORAY JC; PEARSON IG
    Nature; 1960 Apr; 186():252-3. PubMed ID: 13802700
    [No Abstract]   [Full Text] [Related]  

  • 27. Evidence for high genetic diversity of NAD1 and COX1 mitochondrial haplotypes among triclabendazole resistant and susceptible populations and field isolates of Fasciola hepatica (liver fluke) in Australia.
    Elliott T; Muller A; Brockwell Y; Murphy N; Grillo V; Toet HM; Anderson G; Sangster N; Spithill TW
    Vet Parasitol; 2014 Feb; 200(1-2):90-6. PubMed ID: 24360656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica.
    Robinson MW; Lawson J; Trudgett A; Hoey EM; Fairweather I
    Parasitol Res; 2004 Feb; 92(3):205-10. PubMed ID: 14652740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The activity of triclabendazole against immature and adult Fasciola hepatica infections in sheep.
    Smeal MG; Hall CA
    Aust Vet J; 1983 Nov; 60(11):329-31. PubMed ID: 6667209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver fluke isolates: a question of provenance.
    Fairweather I
    Vet Parasitol; 2011 Feb; 176(1):1-8. PubMed ID: 21227593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the effective dose of an experimental intramuscular formulation against immature and adult Fasciola hepatica in sheep.
    Ibarra-Velarde F; Vera-Montenegro Y; Flores-Ramos M; Cantó-Alarcon GJ; Hernández-Campos A; Alcala-Canto Y; Castillo R
    Vet Parasitol; 2018 Aug; 260():38-44. PubMed ID: 30197011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Threat of Triclabendazole Resistance in Fasciola hepatica.
    Kelley JM; Elliott TP; Beddoe T; Anderson G; Skuce P; Spithill TW
    Trends Parasitol; 2016 Jun; 32(6):458-469. PubMed ID: 27049013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of some anti-fluke drugs on immature forms of Fasciola hepatica].
    Chowaniec W; Darski J
    Wiad Parazytol; 1972; 18(1):79-81. PubMed ID: 5026994
    [No Abstract]   [Full Text] [Related]  

  • 34. Population dynamics of the liver fluke, Fasciola hepatica: the effect of time and spatial separation on the genetic diversity of fluke populations in the Netherlands.
    Walker SM; Johnston C; Hoey EM; Fairweather I; Borgsteede F; Gaasenbeek C; Prodöhl PA; Trudgett A
    Parasitology; 2011 Feb; 138(2):215-23. PubMed ID: 20800016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in energy metabolism of the juvenile Fasciola hepatica during its development in the liver parenchyma.
    Tielens AG; van den Heuvel JM; van den Bergh SG
    Mol Biochem Parasitol; 1982 Nov; 6(5):277-86. PubMed ID: 7177167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fasciola hepatica: a review of the economic impact in cattle and considerations for control.
    Kaplan RM
    Vet Ther; 2001; 2(1):40-50. PubMed ID: 19753697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fasciola hepatica demonstrates high levels of genetic diversity, a lack of population structure and high gene flow: possible implications for drug resistance.
    Beesley NJ; Williams DJ; Paterson S; Hodgkinson J
    Int J Parasitol; 2017 Jan; 47(1):11-20. PubMed ID: 27940066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of anti-fluke drugs against young specimens of Fasciola hepatica].
    Chowaniec W; Darski J
    Wiad Parazytol; 1973; 19(2):183-5. PubMed ID: 4714761
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro effects of certain anthelmintic drugs on histochemically demonstrable cholinesterases and succinate oxidase of Fasciola hepatica.
    Panitz E; Knapp SE
    Am J Vet Res; 1970 Apr; 31(4):763-70. PubMed ID: 5437112
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of an injectable combination anthelmintic (nitroxynil+clorsulon+ivermectin) against early immature Fasciola hepatica compared to triclabendazole combination flukicides given orally or topically to cattle.
    Hutchinson GW; Dawson K; Fitzgibbon CC; Martin PJ
    Vet Parasitol; 2009 Jun; 162(3-4):278-84. PubMed ID: 19375232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.